Antithrombotic therapy for ischemic stroke patients complicated with non-valvular atrial fibrillation in grass-roots hospital
10.3760/cma.j.issn.1008-6706.2019.17.011
- VernacularTitle: 基层医院缺血性脑卒中合并非瓣膜性心房颤动的抗栓治疗研究
- Author:
Yue GAO
1
;
Junfei JIANG
Author Information
1. Department of Pharmacy, the Central Hospital of Songjiang District, Shanghai 201600, China
- Publication Type:Journal Article
- Keywords:
Stroke;
Atrial fibrillation;
Anticoagulants;
Warfarin;
International normalized ratio
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(17):2093-2096
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the status of antithrombotic therapy for ischemic stroke patients complicated with non-valvular atrial fibrillation(NVAF) in grass-roots hospitals, and to provide evidence for rational use of drugs in clinic.
Methods:From January 2018 to December 2018, the age, gender, previous history of stroke, history of atrial fibrillation, CHA2DS2-VASc score, HAS-BLED score and other clinical data of 102 ischemic stroke patients complicated with NVAF in the department of neurology of the Central Hospital of Songjiang District were retrospectively analyzed.The using of antithrombotic drugs and the international standardized ratio(INR) before and after hospitalization were also compared.
Results:The antithrombotic therapy of ischemic stroke combined with NVAF was mainly anti-platelet, accounting for 47.06%(48/102), and warfarin anticoagulation accounted for 33.33%(34/102). The initial dose of warfarin 1.25mg accounted for 90.32%(31/34), and the rate of INR reaching the standard(2.0~3.0) was low, accounting for 23.53%(24/102).
Conclusion:The antithrombotic status of patients with ischemic stroke complicated with NVAF in grass-roots hospitals is not ideal, and the utilization rate and standard rate of warfarin are low, which is not in accordance with the requirements of the guidelines.In view of this situation, clinical pharmacists can actively carry out anticoagulant management in conjunction with medical care, and work together to create a safe, effective and economical anticoagulant system for patients with atrial fibrillation.
